GLP1R and obesity disorder: As opposed to singular incretin effects, oxyntomodulin (OXM) activates glucagon receptors (GCGR) and glucagon‐like peptide‐1 receptors (GLP1R), demonstrating a more dynamic range of effects that are more likely to align with evolving ‘health gains’ goals in obesity care.